WAVE Life Sciences (WVE) IPO Opens 7% Higher

Today's IPO for WAVE Life Sciences Ltd. (NASDAQ: WVE) opened for trading at $17.05 after pricing 6,375,000 ordinary shares at a price to the public of $16.00 per share.

Jefferies and Leerink Partners are acting as joint book-running managers for the offering. JMP Securities and SunTrust Robinson Humphrey are acting as co-managers for the offering.

WAVE Life Sciences is a preclinical biopharmaceutical company using our proprietary synthetic chemistry drug development platform to design, develop and commercialize a broad pipeline of first-in-class or best-in-class stereopure nucleic acid therapeutics candidates. By precisely controlling stereochemistry, we are able to design and synthesize therapeutically optimized stereopure nucleic acid therapeutics. Our goal is to develop disease-modifying drugs for indications with a high degree of unmet medical need, in both orphan and broad diseases, and in doing so ultimately deliver exceptional treatment options to patients.

You May Also Be Interested In

• Karman Line Acquisition closes $200M IPO on Nasdaq
• Jefferies Upgrades Fortescue Metals Group Ltd. (FMG:AU) (FSUGY) to Hold
• Non-Invasive Monitoring Systems files to offer 8.1M shares